| Title | [The Medical management of cushing's syndrome.] | | Author(s) | Leal-Cerro A, Soto Moreno A, Angel Mangas M, León Justel A, Webb S | | Institution | Instituto de Biomedicina de Sevilla. I/CSIC/Universidad de Sevilla y Unidad de Gestión de Endocrinología. Hospital Universitario Virgen del Rocío. Sevilla. España. | | Source | Endocrinol Nutr 2009 Apr; 56(4):187-94. | | Abstract | Cushing's syndrome results from prolonged exposure to excessive circulating glucocorticosteroids and is associated with significant morbidity and mortality. While the treatment of choice in most patients is surgical, the metabolic consequences of this syndrome, including hypertension and diabetes mellitus, increase the risks of such surgery. Hypercortisolemia and its sequelae can be efficiently reversed or controlled using medical therapy, either as a temporary measure prior to definitive treatment or as a longer-term treatment in some particularly difficult cases. Drug treatment has been targeted at the hypothalamic/pituitary level, the adrenal glands and at glucocorticoid receptors. The present review discusses the pharmacotherapeutic agents that have been used in Cushing's syndrome and the criteria for their use, as well as recent drugs that may improve the medical treatment of this complex endocrinological disorder in the future. Finally, the shortand long-term follow-up of patients with Cushing's syndrome after surgery is also discussed. | | Language | spa | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19627735 |
|
